Scarica l'app Stockscreener
1.09
1.87%
0.02
Dopo l'orario di chiusura:
1.14
0.05
+4.59%
Fate Therapeutics Inc Borsa (FATE) Ultime notizie
BofA Securities Adjusts Fate Therapeutics Price Target to $2 From $2.20, Maintains Neutral Rating - MarketScreener
Fate Therapeutics' Price Target Cut to $2.50 by Wells Fargo - AInvest
Barclays Maintains Buy Rating on Fate Therapeutics with $2.00 Price Target - AInvest
Is Now a Good Time to Reenter Fate Therapeutics Inc.Risk Management & Low Drawdown Momentum Trade Ideas - newsyoung.net
Fate Therapeutics Announces Corporate Restructuring Plan - MSN
Fate Therapeutics Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Fate Therapeutics’ SWOT analysis: biotech stock navigates clinical progress amid financial challenges - Investing.com
Fate Therapeutics Faces Nasdaq Delisting Risk: Implications for Investors - TipRanks
Fate Therapeutics Reports Q2 2025 Financial Results - TipRanks
Fate Therapeutics Soars 28% on Earnings Optimism and Strategic Shifts - AInvest
Fate Therapeutics shares surge 26.07% intraday after Q2 earnings beat expectations and cash runway extended to 2027. - AInvest
A Quick Look at Today's Ratings for Fate Therapeutics(FATE.US), With a Forecast Between $2 to $6 - 富途牛牛
Fate Therapeutics: Q2 Earnings Snapshot - Greenwich Time
Wells Fargo lowers Fate Therapeutics stock price target to $2.50 on cost cuts - Investing.com Canada
Fate Therapeutics 2025 Q2 Earnings Narrowed Losses but Revenue Falls Sharply - AInvest
Fate Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates - GlobeNewswire
Bullish Divergence Spotted in Fate Therapeutics Inc. MomentumAccurate Buy Point for Momentum Stocks Detected - sundaytimes.kr
Fate Therapeutics earnings beat by $0.05, revenue topped estimates - Investing.com Canada
Fate Therapeutics (FATE) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Fate Therapeutics' Q2 2025 Earnings: A Strategic Catalyst for Long-Term Shareholder Value - AInvest
Fate Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Can machine learning forecast Fate Therapeutics Inc. recoveryBuy Opportunity Forecast for Fast Traders - Newser
What makes Fate Therapeutics Inc. stock price move sharplyHigh Conviction Stock Long-Term Summary - Newser
Why Fate Therapeutics Inc. stock attracts strong analyst attentionFree Real Time Trade Opportunity Alerts - Newser
Analyzing net buyer seller activity in Fate Therapeutics Inc.Free Entry and Exit Strategy Optimizer Tool - Newser
Fate Therapeutics Inc. stock trend forecastFree Risk Controlled Picks With Real Returns - Newser
Fate Therapeutics Inc expected to post a loss of 34 cents a shareEarnings Preview - TradingView
Trapped Investors in Fate Therapeutics Inc. Await Breakout SignalWatchlist for Smart Swing Trading Updated - metal.it
Fate Therapeutics shares fall 4.52% intraday due to unspecified reasons. - AInvest
Full technical analysis of Fate Therapeutics Inc. stockSwing Trade Picks with High Potential - Newser
Fate Therapeutics shares fall 4.17% intraday after granting non-qualified stock options to a new employee. - AInvest
Fate Therapeutics CEO Makes a Notable Stock Sale! - TipRanks
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Fate Therapeutics' Strategic Talent Acquisition and Equity Incentive Program: A Catalyst for Biotech Innovation and Shareholder Value - AInvest
Fate Therapeutics reports new employee inducement awards - MarketScreener
Fate Therapeutics CEO Valamehr sells $15,396 in stock By Investing.com - Investing.com Nigeria
Fate Therapeutics CEO Valamehr sells $15,396 in stock - Investing.com
Cwm LLC Buys 37,290 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Fate Therapeutics (NASDAQ:FATE) Upgraded at Wall Street Zen - Defense World
Fate Therapeutics Inc. Nearing Breakout Level After BounceAccurate Technical Trend Reversal Picks Detected - metal.it
What catalysts could drive Fate Therapeutics Inc. stock higher in 2025Capitalize on trading strategies that deliver - Jammu Links News
What is the dividend policy of Fate Therapeutics Inc. stockFree Stock Market Return Analysis - Jammu Links News
How strong is Fate Therapeutics Inc. company’s balance sheetFree Capital Efficiency Planning - Jammu Links News
How does Fate Therapeutics Inc. generate profit in a changing economyFree Stock Market Trend Analysis - Jammu Links News
Wells Fargo Maintains Fate Therapeutics(FATE.US) With Hold Rating, Maintains Target Price $4 - 富途牛牛
What is Fate Therapeutics Inc. company’s growth strategyUnlock exclusive stock market insights - Jammu Links News
What are Fate Therapeutics Inc. company’s key revenue driversUnlock powerful trading signals and alerts - Jammu Links News
How does Fate Therapeutics Inc. compare to its industry peersBuild a diversified portfolio for risk mitigation - Jammu Links News
Does Fate Therapeutics Inc. stock perform well during market downturnsMassive stock growth - Jammu Links News
Is Fate Therapeutics Inc. a growth stock or a value stockInvest confidently with market-leading analysis - Jammu Links News
Fate Therapeutics’ Phase 1 Study: A New Hope for Autoimmune Diseases - TipRanks
0.41%
0.88%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):